Sling Therapeutics raises $123 million for thyroid eye disease late-stage trial
Sling Therapeutics said it raised $123 million to advance a late-stage trial of its experimental oral drug for thyroid eye disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.